Basel, 3 May 2018 – The Swiss biotech industry has reached record figures for 2017 in financing, infrastructure investment, and exports. This shows that confidence in its ability to create value and innovate remains unshaken. The most prominent example is the acquisition of Actelion by Johnson & Johnson, which, at almost USD 30 billion, was the largest stock exchange transaction worldwide within the life sciences industry over the past year.
Swiss biotech companies continue to be attractive on the world market, and they remain on the radar of global pharma and biotech companies. Switzerland has not only a highly specialized workforce, but also a dense supply network and a high level of availability of suppliers and service companies across all stages of the value chain. These virtually ideal framework conditions are one of the main reasons why both domestic and foreign biotech and pharma companies invested heavily in the production infrastructure in Switzerland in the past and continue to do so now.
Due to its consistently high level of innovation, future prospects are also very promising: The solid development pipeline of the Swiss biotech industry and the quality of its patents, half of which are “world class patents” with a particularly high potential for value creation, will secure Swiss biotechnology’s place on the global market as a strong, competitive sector in the long term.
Up-to-date information about the Swiss Biotech sector is provided in the Swiss Biotech Report 2018, to which scienceindustries contributed. The report was presented May 3, 2018 at the Swiss Biotech Day in Basel (Swiss Biotech media release).
The federal government's «Energy Strategy 2050» jeopardizes the security of electricity supplies and the competitiveness of Switzerland’s exporting industry. scienceindustries is therefore fundamentally opposed to the «Energy Strategy 2050».
